Elicio Therapeutics, Inc. — Investor Relations & Filings
Filings indexed
348
across all filing types
Latest filing
2026-03-17
Regulatory Filings
Country
US
United States of America
Listing
US
ELTX
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company that develops immunotherapies for cancer treatment. The company utilizes its proprietary Amphiphile (AMP) platform to deliver vaccines, immunomodulators, and adjuvants directly to the lymph nodes. This targeted-delivery approach is designed to bind therapeutic agents to albumin, a protein in the bloodstream, facilitating their transport to the immune system's central hubs. The goal is to generate a robust and durable immune response by activating and amplifying cancer-fighting T cells. Elicio's pipeline focuses on aggressive cancers, with a lead program in pancreatic ductal adenocarcinoma (PDAC).
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| EFFECT - Elicio Therapeutics, Inc. (0001601485) (Filer) | 2026-03-17 | English | |
| S-3/A - ELICIO THERAPEUTICS, INC. (0001601485) (Filer) | 2026-03-02 | English | |
| S-3 - ELICIO THERAPEUTICS, INC. (0001601485) (Filer) | 2026-02-27 | English | |
| 4 Filing | 2026-02-03 | English | |
| 4 Filing | 2026-02-03 | English | |
| 4 Filing | 2026-02-03 | English |
Browse filings by year
10 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 32962991 | EFFECT - Elicio Therapeutics, Inc. (0001601485) (Filer) | 2026-03-17 | English | ||
| 32894877 | S-3/A - ELICIO THERAPEUTICS, INC. (0001601485) (Filer) | 2026-03-02 | English | ||
| 32894878 | S-3 - ELICIO THERAPEUTICS, INC. (0001601485) (Filer) | 2026-02-27 | English | ||
| 30835747 | 4 Filing | 2026-02-03 | English | ||
| 30835717 | 4 Filing | 2026-02-03 | English | ||
| 30835672 | 4 Filing | 2026-02-03 | English | ||
| 30835652 | 4 Filing | 2026-02-03 | English | ||
|
2025
8 filings
| |||||
| 12755907 | FORM 4 | 2025-12-10 | English | ||
| 12755908 | Regulatory Filings 2025 | 2025-12-04 | English | ||
| 12755909 | S-3 | 2025-11-13 | English | ||
| 12755910 | 10-Q | 2025-11-13 | English | ||
| 12755912 | 8-K | 2025-11-13 | English | ||
| 12755914 | Major Shareholding Notification 2025 | 2025-10-07 | English | ||
| 12755911 | 8-K | 2025-09-17 | English | ||
| 12755913 | 8-K | 2025-08-12 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AIM ImmunoTech Inc.
Immuno-pharma company developing therapeutics for oncology,…
|
AIM | US | Professional, scientific and te… |
|
Ainos, Inc.
Develops AI-driven diagnostics, immune therapeutics, and te…
|
AIMD | US | Professional, scientific and te… |
|
Akela Pharma Inc.
Integrated drug developer focused on pain and inhalation, p…
|
— | CA | Professional, scientific and te… |
|
Akero Therapeutics, Inc.
Clinical-stage company developing treatments for serious me…
|
AKRO | US | Professional, scientific and te… |
|
Aladdin Healthcare Technologies SE
Develops AI-powered tools for drug discovery and diagnostic…
|
NMI | DE | Professional, scientific and te… |
|
Alamar Biosciences, Inc.
Powering precision proteomics for earliest disease detectio…
|
ALMR | US | Professional, scientific and te… |
|
Alaunos Therapeutics, Inc.
Clinical-stage immuno-oncology company developing TCR-T cel…
|
TCRT | US | Professional, scientific and te… |
|
ALGORAE PHARMACEUTICALS LIMITED
Biopharmaceutical firm using AI to develop neurodegenerativ…
|
1AI | AU | Professional, scientific and te… |
|
Aligos Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing thera…
|
ALGS | US | Professional, scientific and te… |
|
Allelix Biopharmaceuticals Inc.
Biopharmaceutical R&D focused on protein-based drugs and ne…
|
ALX | CA | Professional, scientific and te… |
Elicio Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33784/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33784 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33784 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33784 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33784}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Elicio Therapeutics, Inc. (id: 33784)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.